Leerink Partnrs Issues Positive Forecast for NAMS Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Research analysts at Leerink Partnrs boosted their Q3 2025 earnings estimates for shares of NewAmsterdam Pharma in a research report issued on Wednesday, August 6th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn ($0.41) per share for the quarter, up from their previous forecast of ($0.47). The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at ($0.43) EPS.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.37. The firm had revenue of $19.15 million for the quarter, compared to analysts’ expectations of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%.

Other research analysts have also recently issued reports about the stock. Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They set a “buy” rating and a $44.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma in a report on Wednesday, June 4th. They set an “overweight” rating and a $42.00 target price on the stock. Citigroup assumed coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They set a “buy” rating and a $42.00 target price on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, July 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Moderate Buy” and an average price target of $41.20.

NewAmsterdam Pharma Stock Down 3.7%

NewAmsterdam Pharma stock opened at $24.37 on Monday. The stock has a market cap of $2.74 billion, a P/E ratio of -15.04 and a beta of -0.02. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $27.29. The company’s 50-day moving average price is $20.84 and its two-hundred day moving average price is $19.98.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Quarry LP bought a new position in NewAmsterdam Pharma in the first quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in NewAmsterdam Pharma in the fourth quarter valued at approximately $50,000. National Bank of Canada FI acquired a new stake in NewAmsterdam Pharma in the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. boosted its position in NewAmsterdam Pharma by 19.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company’s stock valued at $80,000 after buying an additional 596 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in NewAmsterdam Pharma by 130.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company’s stock valued at $123,000 after buying an additional 3,390 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, COO Douglas F. Kling sold 100,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $19.29, for a total value of $1,929,000.00. Following the transaction, the chief operating officer directly owned 44,000 shares of the company’s stock, valued at $848,760. This trade represents a 69.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James N. Topper acquired 8,584 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The stock was purchased at an average cost of $19.50 per share, for a total transaction of $167,388.00. Following the completion of the purchase, the director directly owned 3,022,153 shares of the company’s stock, valued at $58,931,983.50. The trade was a 0.28% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 12,364 shares of company stock worth $236,839 and sold 198,612 shares worth $4,025,887. Company insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.